OtherBASIC SCIENCE INVESTIGATIONS
18F-FDG and 18F-FLT Uptake Early After Cyclophosphamide and mTOR Inhibition in an Experimental Lymphoma Model
Lieselot Brepoels, Sigrid Stroobants, Gregor Verhoef, Tjibbe De Groot, Luc Mortelmans and Christiane De Wolf-Peeters
Journal of Nuclear Medicine July 2009, 50 (7) 1102-1109; DOI: https://doi.org/10.2967/jnumed.109.062208
Lieselot Brepoels
Sigrid Stroobants
Gregor Verhoef
Tjibbe De Groot
Luc Mortelmans
Christiane De Wolf-Peeters
In this issue
Journal of Nuclear Medicine
Vol. 65, Issue 4
April 1, 2024
18F-FDG and 18F-FLT Uptake Early After Cyclophosphamide and mTOR Inhibition in an Experimental Lymphoma Model
Lieselot Brepoels, Sigrid Stroobants, Gregor Verhoef, Tjibbe De Groot, Luc Mortelmans, Christiane De Wolf-Peeters
Journal of Nuclear Medicine Jul 2009, 50 (7) 1102-1109; DOI: 10.2967/jnumed.109.062208
18F-FDG and 18F-FLT Uptake Early After Cyclophosphamide and mTOR Inhibition in an Experimental Lymphoma Model
Lieselot Brepoels, Sigrid Stroobants, Gregor Verhoef, Tjibbe De Groot, Luc Mortelmans, Christiane De Wolf-Peeters
Journal of Nuclear Medicine Jul 2009, 50 (7) 1102-1109; DOI: 10.2967/jnumed.109.062208
Related Articles
Cited By...
- A Personalized Preclinical Model to Evaluate the Metastatic Potential of Patient-Derived Colon Cancer Initiating Cells
- [18F]-FLT Positron Emission Tomography Can Be Used to Image the Response of Sensitive Tumors to PI3-Kinase Inhibition with the Novel Agent GDC-0941
- FLT-PET Is Superior to FDG-PET for Very Early Response Prediction in NPM-ALK-Positive Lymphoma Treated with Targeted Therapy
- [18F]FLT-PET Imaging Does Not Always "Light Up" Proliferating Tumor Cells
- Phase I Trial of Cixutumumab Combined with Temsirolimus in Patients with Advanced Cancer
- Can Evaluation of Targeted Therapy in Oncology Be Improved by Means of 18F-FLT?
- 18F-FLT PET as a Surrogate Marker of Drug Efficacy During mTOR Inhibition by Everolimus in a Preclinical Cisplatin-Resistant Ovarian Tumor Model
- Monitoring Tumor Response to Therapy with 18F-FLT PET